Tharimmune Announces Upcoming Conference Presentations
Tharimmune (NASDAQ:THAR), a clinical-stage biotech company, announces participation in two major conferences. At the American College of Gastroenterology Annual Scientific Meeting (October 25-30, Philadelphia), Dr. Nir Barak will present Phase 1 trial results of TH104 in a poster focused on safety and tolerability in cholestatic liver disease patients.
Additionally, CEO Randy Milby will present at the 2024 ThinkEquity Conference on October 30 in New York, offering one-on-one meetings with investors. The ThinkEquity presentation will be available via webcast, with replay access for 90 days.
Tharimmune (NASDAQ:THAR), una società biotecnologica in fase clinica, annuncia la partecipazione a due importanti conferenze. Durante la Conferenza Scientifica Annuale dell'American College of Gastroenterology (dal 25 al 30 ottobre, Filadelfia), il Dr. Nir Barak presenterà i risultati della fase 1 dello studio clinico su TH104 in un poster focalizzato su sicurezza e tollerabilità nei pazienti con malattie epatiche colostatiche.
Inoltre, il CEO Randy Milby presenterà alla ThinkEquity Conference 2024 il 30 ottobre a New York, offrendo incontri one-to-one con gli investitori. La presentazione alla ThinkEquity sarà disponibile tramite webcast, con accesso alla registrazione per 90 giorni.
Tharimmune (NASDAQ:THAR), una empresa biotecnológica en etapa clínica, anuncia su participación en dos importantes conferencias. En la Reunión Científica Anual del American College of Gastroenterology (del 25 al 30 de octubre, Filadelfia), el Dr. Nir Barak presentará los resultados del ensayo de fase 1 de TH104 en un cartel centrado en la seguridad y tolerabilidad en pacientes con enfermedad hepática colestásica.
Además, el CEO Randy Milby presentará en la Conferencia ThinkEquity 2024 el 30 de octubre en Nueva York, ofreciendo reuniones uno a uno con los inversores. La presentación de ThinkEquity estará disponible a través de un webcast, con acceso a la repetición durante 90 días.
Tharimmune (NASDAQ:THAR)는 임상 단계의 생명공학 회사로, 두 개의 주요 컨퍼런스에 참여한다고 발표했습니다. 미국 소화기학회 연례 과학 회의에서 (10월 25-30일, 필라델피아), 닐 바라크 박사는 담즙배액 간질환 환자에서의 안전성과 내약성에 중점을 둔 포스터에서 TH104의 1상 시험 결과를 발표할 예정입니다.
추가로, CEO 랜디 밀비는 10월 30일 뉴욕에서 2024 ThinkEquity Conference에서 발표하며, 투자자와의 일대일 미팅을 제공합니다. ThinkEquity 발표는 웹 캐스트를 통해 제공되며, 재생에 대한 접근은 90일 동안 가능할 것입니다.
Tharimmune (NASDAQ:THAR), une entreprise de biotechnologie en phase clinique, annonce sa participation à deux grandes conférences. Lors de la Réunion Scientifique Annuelle de l'American College of Gastroenterology (du 25 au 30 octobre, Philadelphie), le Dr. Nir Barak présentera les résultats de l'essai de phase 1 de TH104 dans un poster axé sur la sécurité et la tolérance chez les patients souffrant de maladies hépatiques cholestatiques.
De plus, le PDG Randy Milby fera une présentation lors de la Conférence ThinkEquity 2024 le 30 octobre à New York, offrant des réunions individuelles avec les investisseurs. La présentation de ThinkEquity sera disponible en webcast, avec un accès à la rediffusion pendant 90 jours.
Tharimmune (NASDAQ:THAR), ein biopharmazeutisches Unternehmen in der klinischen Phase, kündigt die Teilnahme an zwei bedeutenden Konferenzen an. Auf der Jahrestagung des American College of Gastroenterology (25.-30. Oktober, Philadelphia) wird Dr. Nir Barak die Ergebnisse der Phase-1-Studie zu TH104 in einem Poster vorstellen, das sich auf Sicherheit und Verträglichkeit bei Patienten mit cholestatischer Lebererkrankung konzentriert.
Darüber hinaus wird CEO Randy Milby am 30. Oktober in New York auf der ThinkEquity Conference 2024 präsentieren und Einzelgespräche mit Investoren anbieten. Die Präsentation bei ThinkEquity wird über einen Webcast verfügbar sein, mit einem Zugriff auf die Wiederholung für 90 Tage.
- None.
- None.
BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.
Nir Barak, M.D., Chief Medical Advisor, will present new results from the Company's Phase 1 trial of TH104 in a poster titled "P1780: Safety and Tolerability of TH104, Buccal Nalmefene, in Patients with Cholestatic Liver Disease and Pruritus," at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 25-30 in Philadelphia.
Event: | ACG 2024 Annual Scientific Meeting |
Date: | Monday, October 28, 2024 |
Time: | 10:30 a.m. - 4:00 p.m. Eastern Time |
Location: | Exhibit Hall Poster Session, Pennsylvania Convention Center |
Randy Milby, Chief Executive Officer, will present at the 2024 ThinkEquity Conference being held on October 30, 2024 in New York and hold one-on-one meetings. Interested investors can register to attend the conference and schedule meetings here.
Event: | 2024 ThinkEquity Conference |
Date: | Wednesday, October 30, 2024 |
Time: | 12:00 p.m. Eastern Time |
Location: | The Mandarin Oriental Hotel |
Webcast: |
A replay of the webcast at the ThinkEquity conference will be available for 90 days.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding Tharimmune's or Intract's future financial or operating performance, the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's and Intract's expectations with respect to the Merger, including the timing of entering into a definitive agreement, the timing of closing thereof, the pro forma ownership of the combined company, anticipated financing plans, the combined company's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, Tharimmune and Intract's management. Tharimmune may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by Tharimmune from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Tharimmune's and Intract's views as of the date of this release. Subsequent events and developments may cause Tharimmune's views to change; however, Tharimmune does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing Tharimmune's views as of any date subsequent to the date of this release.
Contacts:
Tharimmune, Inc.
ir@tharimmune.com
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
Contact Information
Tirth Patel
LHA Investor Relations
tpatel@lhai.com
1-212-201-6614
SOURCE: Tharimmune, Inc.
View the original press release on accesswire.com
FAQ
What will Tharimmune (THAR) present at the ACG 2024 Annual Scientific Meeting?
When is Tharimmune's (THAR) presentation at the 2024 ThinkEquity Conference?
How long will the webcast replay be available for Tharimmune's (THAR) ThinkEquity Conference presentation?
What is TH104, the drug being presented by Tharimmune (THAR)?
